Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life

Enrico Cortesi, Pere Gascón, David Henry, Timothy Littlewood, Robert Milroy, Paolo Pronzato, Uwe Reinhardt, Daniel Shasha, Nicholas Thatcher, Peter Wilkinson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level
    Original languageEnglish
    Pages (from-to)22-32
    Number of pages10
    JournalOncology
    Volume68
    Issue number1
    DOIs
    Publication statusPublished - 2005

    Keywords

    • Anemia
    • Cancer
    • Epoetin alfa
    • Fatigue
    • Quality of life

    Fingerprint

    Dive into the research topics of 'Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life'. Together they form a unique fingerprint.

    Cite this